Table 2.
Metabolic variables at baseline, at week 16 (on NucleomaxX) and at week 32 (off NucleomaxX)
| Parameter median (range) | Baseline (n=16) | Week 16 (n=14) | Week 32 (n=14) |
|---|---|---|---|
| BMI (kg/m2) | 25.0 (19–30) | 25.0 (21.5–29.3) | 24.6 (20.5–29.3) |
| Lipoatrophy score (by patient) | 7.5 (4–12) | 4 (0–12)* | 4 (0–12)* |
| Lipoatrophy score (by physician) | 9.5 (4–12) | 6.5 (0–10)* | 5.5 (0–12)* |
| Lipohypertrophy score (by patient) | 2.0 (0–12) | 1 (0–10)* | 1.5 (0–9)* |
| Lipohypertrophy score (by physician) | 1.0 (0–9) | 0 (0–7) | 1.0 (0–6)* |
| Lactate (mmol/l) | 0.9 (0.7–2.0) | 1.1 (0.6–2.0) | 1.0 (0.5–2.2) |
| Insulin (mIU/l) | 7.8 (3.0–24.0) | 8.0 (2.4–28.0) | 7.2 (4–23) |
| HOMA-IR | 0.95 (0.40–1.80) | 1.00 (0.40–3.60) | 0.90 (0.50–3.10) |
| Glucose (mg/dl) | 83 (66–99) | 81 (64–100) | 80 (63–119) |
| Cholesterol (mg/dl) | 196 (123–333) | 189 (134–358) | 178 (133–350) |
| Non-HDL cholesterol(mg/dl) | 146 (101–292) 143 | (95–315) | 136 (97–302) |
| Triglycerides (mg/dl) | 142 (53–297) | 130 (48–634) | 113 (52–265) |
| Fat mtDNA (copies/cell) | 190 (72–549) | 185 (90–506) | 146 (86–414) |
| PBMC mtDNA (copies/cell) | 95 (44–253) | 117 (40–256) | 120 (50–229) |
Abbreviations: BMI, body mass index; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; mtDNA, mitochondrial DNA; PBMC, peripheral blood mononuclear cell.
*
P<0.05 for change from baseline.